The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Pharmacyclics/Janssen; SeaGen; Spectrum Pharmaceuticals
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Jiří Mayer
Research Funding - BeiGene
 
Fontanet Bijou
No Relationships to Disclose
 
Ana C. de Oliveira
Consulting or Advisory Role - Alexion Pharmaceuticals; Janssen
Travel, Accommodations, Expenses - Janssen
 
Yuqin Song
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Michele Merli
No Relationships to Disclose
 
Krimo Bouabdallah
Honoraria - Abbvie; BeiGene; Kite/Gilead; Roche; Sandoz-Novartis; Takeda Science Foundation
Consulting or Advisory Role - Kite/Gilead; Roche; Takeda
Travel, Accommodations, Expenses - Kite/Gilead; Roche; Takeda
 
Peter S. Ganly
No Relationships to Disclose
 
Huilai Zhang
No Relationships to Disclose
 
Sam Yuen
No Relationships to Disclose
 
Ed Kingsley
No Relationships to Disclose
 
Sarit E. Assouline
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech/Roche; Janssen; Novartis; Paladin; Pfizer
Speakers' Bureau - Novartis; Pfizer
Research Funding - Novartis
 
Rebecca Auer
Consulting or Advisory Role - BeiGene; Lilly O.
Speakers' Bureau - BeiGene
Research Funding - Janssen
 
Pil Kim
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Honoraria - BeiGene
 
Adam Greenbaum
Employment - Adaptive Biotechnologies (I); BeiGene; Notch Therapeutics (I)
Stock and Other Ownership Interests - Adaptive Biotechnologies (I); BeiGene
Travel, Accommodations, Expenses - Adaptive Biotechnologies (I); BeiGene; ICON Clinical Research; Notch Therapeutics (I)
 
Sha Huang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Richard Delarue
Employment - BeiGene; Celgene/Bristol-Myers Squibb
Stock and Other Ownership Interests - BeiGene; Celgene/Bristol-Myers Squibb
 
Judith Trotman
Research Funding - BeiGene; Celgene/Bristol-Myers Squibb; Cellectar; Janssen; Pharmacyclics; Roche
(OPTIONAL) Uncompensated Relationships - BeiGene